BeOne Medicines AG Overview
Latest ROE for BeOne Medicines AG: 12.67% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow12.67%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, ONC shows a ROE of 12.67%. That is above the Healthcare sector average of 11.15%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 11.15%. BeOne Medicines AG is at 12.67%, which is higher that average. That is roughly 13.6% above the sector mean. Use the comparison chart on this page to see how ONC stacks up against individual peers as well.
Check the historical chart to see whether ONC's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare BeOne Medicines AG with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has BeOne Medicines AG's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 12.67%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 11.15%, while ONC is at 12.67%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
